Clinical Trials Logo

High Grade Serous Ovarian Cancer clinical trials

View clinical trials related to High Grade Serous Ovarian Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05329545 Terminated - Clinical trials for Fallopian Tube Cancer

Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)

UP-NEXT
Start date: June 23, 2022
Phase: Phase 3
Study type: Interventional

UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC), including fallopian tube and primary peritoneal cancer, expressing high levels of NaPi2b.